《新股消息》內地醫療康養集團祈福醫療提交上市申請
中國的綜合醫療及康養服務供應商祈福醫療向聯交所提交上市申請,獨家保薦人為中泰國際。
據初步招股文件,祈福醫療根據醫養模式提供全面醫療及康養服務,主要於中國廣東省經營廣東祈福醫院、月子中心、護老服務中心、口腔門診部,以及5家零售藥房。截至去年底醫院共有2,100個註冊床位及1,352個營運床位。
去年度集團收入達12.06億元人民幣,按年升39%;盈利按年升1.5倍至1.3億元人民幣。祈福生活服務(03686.HK)主席兼首席執行官孟麗紅作為集團大股東,目前持有上市前全部股權。
集團預期,上市所得款項將用於擴充醫院營運、以擴張康養分部的網絡、作籌辦國際醫學會議、改善科技基建、收購醫院以擴充業務及一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.